Document is current
Any future updates will be listed below
-
Authors
Strelitz, Jean https://orcid.org/0000-0003-4051-6944
Ahern, Amy L.
Long, Gráinne H.
Boothby, Clare E.
Wareham, Nicholas J.
Griffin, Simon J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
isrctn86769081 at ISRCTN.orgDocuments that mention this clinical trial
How good are GPs at adhering to a pragmatic trial protocol in primary care? Results from the ADDITION-Cambridge cluster-randomised pragmatic trial
https://doi.org/10.1136/bmjopen-2016-015295
Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)61422-6
Changes in behaviors after diagnosis of type 2 diabetes and 10-year incidence of cardiovascular disease and mortality
https://doi.org/10.1186/s12933-019-0902-5
-
Funding
Funding for this research was provided by:
Wellcome Trust (G061895)
Medical Research Council (G0001164, MC_UU_12015/4)
NIHR Health Technology Assessment Programme (08/116/300)
NIHR Programme Grants for Applied Research (RP-PG-0606-1259)
- License Information
-
More Information
Article History
Received: 20 May 2019
Accepted: 26 July 2019
First Online: 1 August 2019
Ethical approval and consent to participate
: Informed consent was obtained from all individual participants included in the study. Ethical approval was obtained from local research ethics committees (Cambridge, ref:01/063; Huntingdonshire ref:00/609; Peterborough and Fenland, ref:P01/95; West Essex, ref:1511-0103; North and Mid Essex, ref:MH395 MREC02/5/54; West Suffolk, ref:03/002; Hertfordshire and Bedfordshire, ref:EC03623; and the Eastern Multi-Centre Research Ethics Committee, ref:02/5/54).
: Not applicable.
: SJG reports grants from Wellcome Trust, Medical Research Council, NIHR, NIHR Health Technology Assessment Programme, NHS R&D and the University of Aarhus (Denmark), and provision of equipment from Bio-Rad during the conduct of the study. Outside the submitted work he also reports receiving fees from Novo Nordisk, Astra Zeneca and Napp for speaking at postgraduate education meetings, support to attend a scientific meeting from Napp, and an honorarium and reimbursement of travel expenses from Eli Lilly associated with membership of an independent data monitoring committee for a randomised trial of a medication to lower glucose. ALA is Principal Investigator on two trials where research costs are funded by national research councils (NIHR, NPRI) and the intervention is provided at no cost by Weight Watchers International. The other authors declare that they have no conflicts of interests.
